# Altay Therapeutics **Source:** https://geo.sig.ai/brands/altay-therapeutics **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** altaytx.com **Last Updated:** 2026-04-14 ## Summary Cambridge biotech developing small molecules targeting "undruggable" transcription factors for FSHD and cancer; YC W20 $6.71M competing with Fulcrum Therapeutics in the rare muscle disease therapeutic space. ## Company Overview Altay Therapeutics is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $6.71 million raised including a $3 million seed round — developing first-in-class small molecule therapeutics that target transcription factors, historically considered "undruggable" proteins due to their lack of conventional binding sites, for rare genetic diseases and oncology indications. Founded in 2019, Altay's lead programs focus on facioscapulohumeral muscular dystrophy (FSHD) — a rare, progressive muscle disease affecting 1 in 8,500 people with no approved treatments — and cancer targets where transcription factor dysregulation drives tumor growth. Altay's transcription factor inhibition platform addresses one of the fundamental challenges in drug discovery: transcription factors are proteins that regulate gene expression and are frequently mutated or overactivated in disease, but their flat, featureless binding surfaces have resisted conventional small molecule drug design for decades. Altay's approach uses proprietary computational modeling and medicinal chemistry to identify cryptic binding sites and design small molecules that disrupt protein-protein interactions or DNA binding of disease-relevant transcription factors. For FSHD specifically, the disease is driven by toxic expression of the DUX4 transcription factor — inhibiting DUX4 expression or activity represents the mechanistic target that Altay's lead compounds address. In 2025, Altay Therapeutics competes in the rare disease and oncology drug development market with Fulcrum Therapeutics (FSHD-focused, NASDAQ: FULC, losmapimod for FSHD), Arrowhead Pharmaceuticals (RNA interference for rare diseases), and transcription factor-focused startups for drug development funding and rare disease positioning. FSHD's unmet medical need (progressive muscle weakness, no approved treatment, large untreated patient population) creates orphan drug designation potential and expedited FDA review pathways. Y Combinator's W20 biotech backing connects Altay with the life sciences investor community for future Series A fundraising. The 2025 strategy focuses on completing lead optimization for the FSHD program, generating clinical candidate data package for IND application filing, and establishing partnerships with academic medical centers for natural history data access. ## Frequently Asked Questions ### What is Altay Therapeutics? Altay Therapeutics is a biotechnology company founded in 2019 that develops first-in-class therapeutics targeting transcription factors through innovative small molecule inhibition. The Y Combinator-backed company (W20) focuses on rare genetic diseases and cancer, with lead programs in facioscapulohumeral muscular dystrophy (FSHD) and oncology. ### What products and services does Altay Therapeutics offer? Altay Therapeutics develops transcription factor inhibitors, small molecule therapeutics, and drug candidates for rare diseases and oncology. Their primary focus areas include FSHD therapeutic development and cancer treatments using their proprietary platform. ### Who are the target patients for Altay Therapeutics' treatments? Altay Therapeutics focuses on patients with rare genetic diseases, specifically facioscapulohumeral muscular dystrophy (FSHD), and cancer patients. Their therapeutics target historically undruggable transcription factors in these disease areas. ### When was Altay Therapeutics founded? Altay Therapeutics was founded in 2019 and participated in Y Combinator's Winter 2020 (W20) batch. ### Where is Altay Therapeutics located? Altay Therapeutics is based in San Francisco, California. ### How much funding has Altay Therapeutics raised? Altay Therapeutics has raised $6.71M in total funding, including a $3M seed round. The company is backed by Y Combinator from their Winter 2020 batch. ### What are Altay Therapeutics' key achievements? Altay Therapeutics has successfully raised $6.71M in funding and developed a proprietary platform for creating small molecule inhibitors against historically undruggable transcription factor targets. The company has advanced lead programs in FSHD and oncology indications. ### What technology or approach does Altay Therapeutics use? Altay Therapeutics uses a proprietary platform that enables the development of small molecule inhibitors targeting transcription factors, which have historically been considered undruggable. This innovative approach focuses on first-in-class therapeutics for rare diseases and cancer. ### How can I contact Altay Therapeutics? Altay Therapeutics is located in San Francisco, CA. Additional contact information is not provided in the available company information. ### What are the recent developments at Altay Therapeutics? Recent developments include raising $6.71M in total funding with a $3M seed round and participating in Y Combinator W20. The company is advancing first-in-class transcription factor inhibitors with lead programs in facioscapulohumeral muscular dystrophy (FSHD) and oncology. ## Tags healthtech, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*